{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:51:16Z","timestamp":1791143476769,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1136\/ard.61.suppl_2.ii51","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T19:21:06Z","timestamp":1414005666000},"page":"ii51-ii53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"special_numbering":"S2","title":["Beh\u00e7et's disease: a new target for anti-tumour necrosis factor treatment"],"prefix":"10.1016","volume":"61","author":[{"given":"P P","family":"Sfikakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.61.suppl_2.ii51_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","article-title":"Beh\u00e7et\u2019s disease","volume":"27","author":"Kaklamani","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0002-9343(01)01081-6","article-title":"Beh\u00e7et\u2019s syndrome: Where do we stand?","volume":"112","author":"Yazici","year":"2002","journal-title":"Am J Med"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib3","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib4","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome","volume":"44","author":"Yardacul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et\u2019s syndrome. A randomized, double blind, placebo controlled trial","volume":"128","author":"Hamaryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/sarh.2001.19819","article-title":"Treatment of Beh\u00e7et\u2019s disease: an update","volume":"30","author":"Kaklamani","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease","volume":"i","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin-A versus pulsed cyclophospamide Beh\u00e7et\u2019s syndrome: a single-masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9394(14)72551-6","article-title":"FK506 treatment of noninfectious uveitis","volume":"118","author":"Ishioka","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et\u2019s disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Beh\u00e7et\u2019s disease with Interferon alfa-2a: a pilot study","volume":"82","author":"Kotter","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of Interferon alfa-2a in severe and refractory uveitis associated with Beh\u00e7et\u2019s disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"issue":"suppl 24","key":"10.1136\/ard.61.suppl_2.ii51_bib14","first-page":"S6","article-title":"Beh\u00e7et\u2019s disease : an update on the pathogenesis","volume":"19","author":"Gul","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2249.1997.274-ce1159.x","article-title":"Role of gammadelta T lymphocytes in the development of Beh\u00e7et\u2019s disease","volume":"107","author":"Yamashita","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib16","first-page":"1544","article-title":"Overproduction of monocyte-derive TNF-a, IL-6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. A comparative study with familial Mediterranean fever and healthy subjects","volume":"20","author":"Mege","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib17","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et\u2019s disease; soluble TNFR-75 as a biological marker of disease activity","volume":"24","author":"Turan","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","article-title":"Serum levels of TNF-a, sIL-2R, OL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease","volume":"11","author":"Evereklioglu","year":"2002","journal-title":"Mediators Inflamm"},{"issue":"suppl 4","key":"10.1136\/ard.61.suppl_2.ii51_bib19","first-page":"S708","article-title":"High levels of TNF-a in the in the aqueous humor in patients suffering from Adamantiades-Beh\u00e7et\u2019s disease: preliminary results","volume":"42","author":"Chronopoulou","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis","volume":"33","author":"Santos Lacomba","year":"2001","journal-title":"Ophthalmic Res"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/ard.60.6.637","article-title":"Remission of Beh\u00e7et\u2019s syndrome with tumour necrosis factor a blocking therapy","volume":"60","author":"Goossens","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","article-title":"Treatment of recalcitrant orogenital ulceration of Beh\u00e7et\u2019s syndrome with Infliximab","volume":"40","author":"Robertson","year":"2001","journal-title":"Rheumatology"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","article-title":"Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh\u00e7et\u2019s disease: a case report","volume":"120","author":"Hassard","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Beh\u00e7et\u2019s syndrome with chimeric tumor necrosis factor alpha antibody","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","article-title":"Effect of infliximab on threatening panuveitis in Beh\u00e7et\u2019s disease","volume":"358","author":"Munoz-Fernandez","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.61.3.283-a","article-title":"Remission of Beh\u00e7et\u2019s syndrome with TNFa blocking treatment","volume":"61","author":"Rosenbaum","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/08830189709116845","article-title":"Uveitis in Beh\u00e7et\u2019s disease","volume":"14","author":"Nussenblatt","year":"1997","journal-title":"Int Rev Immunol"},{"key":"10.1136\/ard.61.suppl_2.ii51_bib29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/gast.2001.29035","article-title":"Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn\u2019s disease","volume":"121","author":"van Deventer","year":"2001","journal-title":"Gastroenterology"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724434675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724434675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.61.suppl_2.ii51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:37:24Z","timestamp":1736141844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724434675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":29,"alternative-id":["S0003496724434675"],"URL":"https:\/\/doi.org\/10.1136\/ard.61.suppl_2.ii51","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beh\u00e7et's disease: a new target for anti-tumour necrosis factor treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.61.suppl_2.ii51","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Copyright 2002 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}